Stock Events

Stock Events

Grifols SA 

€5.40
1134
+€0.10+1.89%Thursday 07:03

Statistics

Day High
5.4
Day Low
5.4
52W High
5.55
52W Low
4.64
Volume
0
Avg. Volume
0
Mkt Cap
3.68B
P/E Ratio
-
Dividend Yield
1.53%
Dividend
0.08

Upcoming

Dividends

1.53%Dividend Yield
Jul 2026
€0.04
Aug 2025
€0.08
Jun 2021
€0.18
Nov 2020
€0.08
Dec 2019
€0.10
10Y Growth
-12.43%
5Y Growth
-30.99%
3Y Growth
N/A
1Y Growth
-45.36%

Earnings

Nov 2Expected
Q1 2026
Q2 2026
Q3 2026
0.14
0.19
0.25
0.3
Expected EPS
0.284514016768644
Actual EPS
0.30365436347999997

Financials

5.34%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
7.52BRevenue
402MNet Income

Analyst Ratings

$6.83Average Price Target
The highest estimate is ⁦6.83⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow G0F.MU. It's not an investment recommendation.
Repsol
163
REP.MC
Banco Santander.
150
SAN.MC
Telefonica
149
TEF.MC
Enagas SA
144
ENG.MC

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Carlisle Companies
CSL
Mkt Cap14.54B
CSL Limited is a global biotech leader that develops and delivers innovative biotherapies and influenza vaccines, directly competing with Grifols' plasma-derived products.
Takeda Pharmaceutical
TAK
Mkt Cap66.81B
Takeda Pharmaceutical Company operates in similar therapeutic areas as Grifols, including plasma-derived therapies and vaccines, making them direct competitors.
Baxter International
BAX
Mkt Cap11.9B
Baxter International Inc. produces critical care, nutrition, renal, hospital, and surgical products, including plasma-based therapies that compete with Grifols' offerings.
Biogen
BIIB
Mkt Cap37.49B
Biogen Inc. focuses on neurology, autoimmune and hematologic disorders, areas where Grifols also operates, especially in treatments derived from plasma.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. is a broad-based pharmaceutical company that, among many areas, competes with Grifols in the development of vaccines and treatments for rare diseases.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson engages in the research and development, manufacture, and sale of a broad range of products in the healthcare field, overlapping with Grifols in the production of blood-related products.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie Inc. focuses on pharmaceuticals including plasma-based therapies, directly competing with Grifols in the immunology and oncology therapeutic areas.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. competes with Grifols in the biotechnology space, focusing on innovative human therapeutics, including treatments for illnesses that Grifols also targets.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops and markets medicines in areas of unmet medical need, including liver diseases, where Grifols also operates.
Novo Nordisk
NVO
Mkt Cap176.43B
Novo Nordisk A/S is a global healthcare company with a leading position in diabetes care, but also competes with Grifols in the hemophilia market with their biopharmaceuticals.

About

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
Show More
CEO
Jose Ignacio Abia Buenache
Employees
25247
Country
Spain
ISIN
US3984382008
WKN
000A1C3HH

Listings

F
DE
OZTA.F
MX
MX
GRFPN.MX
STU
DE
OZTA.STU
MI
IT
1GRF.MI

0 Comments

Share your thoughts

FAQs

What is Grifols SA stock price today?▼
The current price of G0F.MU is €5.40 EUR — it has increased by +1.89% in the past 24 hours. Watch Grifols SA stock price performance more closely on the chart.
What is Grifols SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Grifols SA stocks are traded under the ticker G0F.MU.
What is Grifols SA market cap?▼
Today Grifols SA has the market capitalization of 3.68B
When is the next Grifols SA earnings date?▼
Grifols SA is going to release the next earnings report on March 4, 2027.
What were Grifols SA earnings last quarter?▼
G0F.MU earnings for the last quarter are 0.3 EUR per share, whereas the estimation was 0.28 EUR resulting in a +6.73% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Grifols SA revenue for the last year?▼
Grifols SA revenue for the last year amounts to 7.52B EUR.
What is Grifols SA net income for the last year?▼
G0F.MU net income for the last year is 402M EUR.
Does Grifols SA pay dividends?▼
Yes, G0F.MU dividends are paid semi-annual. The last dividend per share was 0.04 . As of today, Dividend Yield (FWD)% is 1.53%.
How many employees does Grifols SA have?▼
As of November 6, 2026, the company has 25,247 employees.
In which sector is Grifols SA located?▼
Grifols SA operates in the Health & Wellness sector.
When did Grifols SA complete a stock split?▼
The last stock split for Grifols SA was on January 4, 2016 with a ratio of 2:1.
Where is Grifols SA headquartered?▼
Grifols SA is headquartered in Barcelona, Spain.